Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy.The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for depileve easy clean antibody therapy.Prompted by this, we used three different CD38 antibody sequences to generate second-generation r